The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
According to a recent study in the Heart journal, regular tub bathing is linked to a lower risk of death from heart disease and stroke.
Study: Rivaroxaban Reduces Risk of Major Venous Thromboembolism Following Nonmajor Orthopedic Surgery
Study shows rivaroxaban (Xarelto, Bayer) following nonmajor orthopedic surgery reduced the risk of major venous thromboembolism by approximately 75% compared with enoxaparin.
Patients with symptomatic peripheral artery disease who took rivaroxaban (Xarelto, Bayer) saw a 15% reduction in the risk of major adverse limb and cardiovascular events.
A recent study has detailed information on the potential dangers and the application of QTc monitoring to guide treatment when using drugs that can cause heart rhythm changes.
A prespecified exploratory analysis using the safety data from the 3 trials indicated fewer major adverse cardiovascular events (MACE) with inclisiran compared with placebo.
All 3 trials reached their primary endpoints, specifically percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 to 18 months.
Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.
Staying on top of oral hygiene may be connected to a lower risk of atrial fibrillation and heart failure.
A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.
Top news of the day from across the health care landscape.
Managing elevated cholesterol is one of the the key elements to decreasing negative outcomes in atherosclerotic cardiovascular disease.
A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.